MedTrace Logo

Dexmedetomidine in Reducing Incidence of Emergence Agitation After Nasal Surgery

NCT05634148 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-04-04

No results posted yet for this study

Summary

Various pharmacological interventions have been attempted previously to prevent postoperative EA with variable results. These include use of opioids, propofol, midazolam, ketamine, magnesium and alpha-2 agonists like clonidine and dexmedetomidine. Dexmedetomidine have been used with different dosages and different timings of administration with variable results and at the expense of major hemodynamic disturbances. The objective of this study was to investigate the role of single dose of dexmedetomidine (0.5 mcg/kg) administered as 30 minutes infusion prior to extubation in reducing the incidence and severity of EA and coughing on extubation.

Conditions

  • Postoperative Delirium

Interventions

DRUG

Dexmedetomidine

Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group

Sponsors & Collaborators

  • Security Forces Hospital

    lead OTHER

Principal Investigators

  • Anwar Huda, FRCA · Security Forces Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2023-04-01
Completion
2023-04-01

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05634148 on ClinicalTrials.gov